Status:

COMPLETED

Fetal Endotracheal Occlusion (FETO) in Severe and Extremely Severe Congenital Diaphragmatic Hernia

Lead Sponsor:

Michael A Belfort

Collaborating Sponsors:

Baylor College of Medicine

Conditions:

Congenital Diaphragmatic Hernia

Eligibility:

FEMALE

18-45 years

Phase:

NA

Brief Summary

Congenital diaphragmatic hernia (CDH) occurs when the diaphragm fails to fully fuse and leaves a portal through which abdominal structures can migrate into the thorax. In the more severe cases, the ab...

Detailed Description

Enrollment Women carrying fetuses with severe or extremely severe CDH and a normal karyotype will undergo routine clinical evaluation. The fetuses will be 27+0/7 to 29+6/7 weeks of gestational age fo...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • Patient is a pregnant woman between 18 and 45 years of age
  • Singleton pregnancy
  • Confirmed diagnosis of severe or extremely severe left, right or bilateral CDH of the fetus
  • Severe CDH: -Fetal liver herniated into the hemithorax -Lung-head ratio (LHR) is less than or equal to 1.0 calculated between 27+0/7 and 29+6/7 weeks' gestation
  • Extremely Severe CDH: -At least 1/3rd of the liver parenchyma herniated into the thoracic cavity -Lung-head ratio (LHR) is \< 0.71 calculated between 22+0/7 and 29+6/7 weeks' gestation
  • Normal fetal echocardiogram or echocardiogram with a minor anomaly (such a small VSD) that in the opinion of the pediatric cardiologist will not affect postnatal outcome
  • Normal fetal karyotype
  • The mother must be healthy enough to have surgery
  • Patient provides signed informed consent that details the maternal and fetal risks involved with the procedure
  • Patient willing to remain in Houston for the duration following the balloon placement until delivery
  • Signed informed consent
  • EXCLUSION CRITERIA:
  • Contraindication to abdominal surgery, fetoscopic surgery, or general anesthesia
  • Allergy to latex
  • Allergy or previous adverse reaction to a study medication specified in this protocol
  • Preterm labor, preeclampsia, or uterine anomaly (e.g., large fibroid tumor)
  • Fetal aneuploidy, known structural genomic variants, other major fetal anomalies, or known syndromic mutation
  • Suspicion of major recognized syndrome (e.g. Fryns syndrome) on ultrasound or MRI
  • Maternal BMI \>40
  • High risk for fetal hemophilia

Exclusion

    Key Trial Info

    Start Date :

    February 21 2012

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 11 2023

    Estimated Enrollment :

    20 Patients enrolled

    Trial Details

    Trial ID

    NCT00881660

    Start Date

    February 21 2012

    End Date

    April 11 2023

    Last Update

    November 14 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Texas Children's Hospital

    Houston, Texas, United States, 77030